Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Talking about the end: could guided conversations reduce futile cancer treatments?

NCT ID NCT05444348

Symptom relief Sponsor: Christoffer Johansen Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 12, 2026 · Last updated Aug 13, 2026 · Updated 1 time

Summary

This trial tests a program called ACT, which trains doctors and nurses to have compassionate, structured conversations with blood cancer patients and their families about end-of-life care. The goal is to help patients understand their prognosis and make informed decisions, potentially reducing the use of chemotherapy in the last month of life and easing anxiety for both patients and caregivers. The study involves about 920 participants across multiple hospitals, with some clinicians using the ACT approach and others providing usual care.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
A structured communication intervention called Advance Consultations Concerning Your Life and Treatment (ACT), involving clinician training, patient preparation, and guided conversations about end-of-life care.
What this could lead to
If effective, this approach could help blood cancer patients and their families make more informed decisions, reduce unnecessary treatments near the end of life, and improve the quality of their final days.
What could go wrong
The trial is relatively small and relies on clinician training and adherence, which may vary. It is uncertain whether the intervention will change outcomes, and it may not be feasible in all clinical settings.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 920 people

The number the study aims to enrol. It can still change while the study runs.

Started

Aug 2022

Expected to finish

Jul 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: Patients must: * Be at least 18 years of age * Have a diagnosis of one of the following: * High-risk myelodysplastic syndrome (MDS) or MDS with overlap of myeloproliferative neoplasms (high-risk MDS/MPN), * Acute myeloid leukemia(AML): Age≥80 or in palliative treatment or relapse * Lymphoma: Age≥80 or relapse or refractory or palliative treatment * Multiple myeloma(MM): Age≥80 or relapsed or refractory Have limited treatment options. Provide informed consent. Have sufficient Danish skills to complete intervention sessions and data collection An informal caregiver is identified by the patient as the primary provider of informal physical, practical or emotional support and must: * Be at least 18 years of age * Be able to accompany patients to intervention appointments * Provide informed consent * Have sufficient Danish skills to complete intervention sessions and data collection Physicians: * specialized in hematology * treating patients with High risk myelodysplastic syndrome, acute myeloid leukemia, lymphoma, or multiple myeloma * work at the same department for the entire time of intervention. Nurses: * treating patients with High-risk myelodysplastic syndrome, acute myeloid leukemia, lymphoma, or multiple myeloma * work at the same department for the entire time of intervention. Exclusion Criteria: Patient and caregiver are excluded if one of them is: \- Suffering from a severe psychiatric disorder Physicians and nurses: \- If they do not meet the inclusion criterion.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Acute myeloid leukemia are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

acute myeloid leukemia lymphoma myelodysplastic syndrome Myelodysplastic Syndromes myelodysplastic/myeloproliferative neoplasm plasma cell myeloma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Acute myeloid leukemia Lymphoma Multiple myeloma Myelodysplastic syndromes

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    7 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Aalborg Universitetshospital

    RECRUITING

    Aalborg, 9100, Denmark

  • Aarhus Universitetshospital

    RECRUITING

    Aarhus, 8200, Denmark

  • Lillebælt syge - Vejle Sygehus

    RECRUITING

    Vejle, 7100, Denmark

  • Odense Universitetshospital

    RECRUITING

    Odense, 5000, Denmark

  • Regionshospitalet Gødstrup

    RECRUITING

    Herning, 7400, Denmark

  • Sjællands universitetshospital Roskilde

    RECRUITING

    Roskilde, 4000, Denmark

  • Sydvestjysk sygehus - Esbjerg

    RECRUITING

    Esbjerg, 6700, Denmark

More trials for these conditions

Other studies related to the condition(s) this trial covers.